Mechanism of Action: Nebulised Salbutamol and Heart Rate Increase
Nebulised salbutamol increases heart rate through two primary mechanisms: direct β2-adrenergic receptor stimulation on cardiac tissue (10-50% of cardiac receptors are β2-receptors) and reflex tachycardia secondary to peripheral vasodilation and decreased systemic vascular resistance. 1
Direct Cardiac β2-Receptor Activation
While salbutamol is designed as a selective β2-agonist targeting bronchial smooth muscle, the human heart contains a significant population of β2-adrenergic receptors comprising 10-50% of total cardiac adrenergic receptors 1. When salbutamol activates these cardiac β2-receptors, it triggers:
- Adenylyl cyclase activation → increased intracellular cyclic AMP
- Protein kinase A activation → enhanced cardiac contractility and chronotropy
- Direct positive chronotropic effect on sinoatrial node
This mechanism explains why even "selective" β2-agonists produce cardiovascular effects, though salbutamol has relatively weaker action on cardiac β1-receptors compared to isoprenaline 2.
Reflex Tachycardia from Peripheral Vasodilation
The second, often predominant mechanism involves:
- β2-receptor activation in vascular smooth muscle → peripheral vasodilation
- Decreased systemic vascular resistance (documented in multiple studies) 3, 4
- Baroreceptor-mediated reflex tachycardia to maintain cardiac output and blood pressure
- Increased cardiac output as a compensatory response 4
Studies in conscious dogs demonstrated that the positive chronotropic effect of salbutamol was "probably mainly reflex in origin" 2, and human studies confirm significant decreases in systemic vascular resistance accompanying heart rate increases 3, 4.
Sympathetic Nervous System Activation
Recent evidence adds a third component: salbutamol acutely increases muscle sympathetic nerve activity (MSNA) 5. This suggests systemic sympathetic activation contributes to the tachycardic response beyond direct receptor effects.
Clinical Magnitude and Significance
The heart rate increase is dose-dependent and clinically measurable:
- Mean increase of 3-10 beats/minute in typical therapeutic doses 6
- Effects are additive with hypoxia (common in acute asthma) 3
- Higher doses via nebulisation produce more pronounced effects than metered-dose inhalers 7
Important Caveats:
- The cardiovascular effects can be clinically significant in patients with underlying cardiac disease, coronary insufficiency, or arrhythmias 1
- Cardiac arrest and death have been reported with excessive use, though the exact mechanism remains unclear 1
- The tachycardia is generally transient and well-tolerated in healthy individuals and most asthmatic patients 6
- No severe cardiac side effects requiring treatment discontinuation were reported in pediatric safety studies 7
The FDA label explicitly warns that these cardiovascular effects, while uncommon at recommended doses, may necessitate drug discontinuation if they occur 1. The mechanism is multifactorial rather than purely β2-selective, explaining why "selective" β2-agonists still produce predictable cardiac effects.